Progress of Bevacizumab in the Front-line Treatment of Advanced Non-small Cell Lung Cancer

Progress of Bevacizumab in the Front-line Treatment of Advanced Non-small Cell Lung Cancer

As the first anti-angiogenesis monoclonal antibody, bevacizumab has been an vital component of front line regimen of advanced nonsqaumous non-small cell lung cancer (NSCLC). It increase the efficacy of chemotherapy, epithelial growth factor receptor tyrosine kinase inhibitors and immune checkpoint i...

Full description

Bibliographic Details
Main Authors: Bin AI, Yifan YANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2020-07-01
Series:Chinese Journal of Lung Cancer
Subjects:
bevacizumab
lung neoplasms
front line treatment
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.34

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.34

Similar Items